Skip to content
NewsBlazeIN – Lifestyle
Author:
Iterion Therapeutics
Iterion Therapeutics Announces Promising Phase 1b Data for Tegavivint in Combination with Osimertinib in First-Line EGFR-Mutated Non-Small Cell Lung Cancer
September 22, 2026
Iterion Therapeutics Strengthens Board with Additions of Manuel Aivado, MD, PhD and Bob Smith
August 12, 2026
Iterion Therapeutics Reports First Clinical Validation of Tegavivint as a Targeted Therapy for Wnt-Driven Advanced HCC in Oral Presentation at 2026 ASCO Annual Meeting
June 1, 2026